SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...

Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing the treatment burden associated ...

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...

A recent study found that the ranibizumab port delivery system (PDS) has cost-saving potential compared with regular ranibizumab or aflibercept injections for age-related macular degeneration if used ...

Treatment of wet AMD-related vision loss is an onerous task for patients and eye doctors alike, typically requiring monthly injections of blood vessel-blocking eye drugs such as Genentech's Lucentis.

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.

Please provide your email address to receive an email when new articles are posted on . Data from the ZIPANGU study showed the use of focal/grid short-pulse laser therapy in patients receiving ...